Drugs / human amniotic mesenchymal stem cell
human amniotic mesenchymal stem cell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04318600 | Jan 2014 → Mar 2017 | lupus nephritis | Yan'an Affiliated Hospital of Kunming Medical University | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | human amniotic mesenchymal stem cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04318600 ↗ |
| Known as | hA-MSC | “human amniotic mesenchymal stem cell (hA-MSC) for the treatment of lupus nephritis patients with WHO class III, IV or V LN were given hA-MSC” NCT04318600 ↗ |
| Known as | hAMSCs | “MSCs originating from the human amniotic membrane (hAMSCs) of the placenta” PMID 35412950 ↗ Apr 2022 |
| Modality | Cell therapy | “cell therapy” NCT04318600 ↗ |
| Route | Intravenous | “Peripheral intravenous infusion” NCT04318600 ↗ |